McElhinney R S, McCormick J E, Bibby M C, Double J A, Atassi G, Dumont P, Pratesi G, Radacic M
Laboratories of the Medical Council of Ireland, Trinity College, Dublin.
Anticancer Drug Des. 1989 Mar;3(4):255-69.
This study considers further changes in the carrier moiety of molecular combinations of the pyrimidine antimetabolite 5-fluorouracil (5-FU) and the alkylating group chloroethylnitrosourea (CNU). Detailed chemical syntheses are described of compounds incorporating (a) a simpler alkoxy group in the 'sugar' fragment, (b) attachment of the 5-FU residue to the C-X-C-C chain on the side of the heteroatom X distal from the CNU group, and (c) higher oxidation states of the sulphur atom in the prototypical compound B.3839. Anti-tumour activity of these analogues against a series of experimental murine colon, lung and mammary tumours is described. The pattern of activity reveals that the carrier moiety is important but further pharmacokinetics and metabolism studies are required to determine structure-activity relationships.
本研究考虑了嘧啶抗代谢物5-氟尿嘧啶(5-FU)与烷基化基团氯乙基亚硝脲(CNU)分子组合中载体部分的进一步变化。描述了化合物的详细化学合成过程,这些化合物包括:(a)在“糖”片段中引入更简单的烷氧基;(b)将5-FU残基连接到远离CNU基团的杂原子X一侧的C-X-C-C链上;(c)原型化合物B.3839中硫原子的更高氧化态。描述了这些类似物对一系列实验性小鼠结肠癌、肺癌和乳腺癌的抗肿瘤活性。活性模式表明载体部分很重要,但需要进一步的药代动力学和代谢研究来确定构效关系。